With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.35857-89-7,6-Chloropyridazine-3-carbonitrile,as a common compound, the synthetic route is as follows.
A solution of (7?)-(-)-N-boc-3-pyrrolidinol (CAS: 109431-87-0; 0.80 g, 4.27 mmol) in DMF (3.31 mL) was added dropwise to a stirred mixture of NaH (60% dispersion in mineral oil, 0.21 g, 5.13 mmol) and l5-crown-5 (1.14 mL, 4.27 mmol) in DMF (3.31 mL) at 0 C. The reaction mixture was stirred at 0 C for 30 min and a solution of 6- chloro-3-pyridazinecarbonitrile (CAS: 35857-89-7; 656 mg, 4.70 mmol) dissolved in DMF (3.1 mL) was added portionwise at 0 C. The resulting mixture was stirred at 80 C for 3 h. The mixture was concentrated in vacuo and the residue was diluted with water and extracted with EtOAc. The organic layer was dried (MgS04), filtered and evaporated in vacuo. The crude product was purified by flash column chromatography (silica, EtOAC in heptane, gradient from 0/100 to 60/40). The desired fractions were collected and concentrated in vacuo to afford intermediate 42 (810 mg, 65%) as a white solid., 35857-89-7
As the paragraph descriping shows that 35857-89-7 is playing an increasingly important role.
Reference£º
Patent; JANSSEN PHARMACEUTICA NV; BARTOLOME-NEBREDA, Jose Manuel; TRABANCO-SUAREZ, Andres, Avelino; MARTINEZ-VITURRO, Carlos Manuel; DELGADO-JIMENEZ, Francisca; CONDE-CEIDE, Susana; VEGA RAMIRO, Juan, Antonio; (178 pag.)WO2019/243527; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem